Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aung Naing

Showing results (251-260 of 397) with videos related to

Pageof 40
Sort By:
Cancer Chemotherapy and Pharmacology|January 18, 2014
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancersJennifer J Wheler, Filip Janku, Gerald S Falchook, et al.
Carcinogenesis|October 3, 2017
Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic modelYoshiko Shimizu, Hideki Furuya, Paulette M Tamashiro, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trialsHossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2018
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With ImmunotherapyChristine M Parseghian, Madhavi Patnana, Priya Bhosale, et al.
Oncotarget|February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trialsIshwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Journal for Immunotherapy of Cancer|November 20, 2024
Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumorsMatthew H Taylor, Aung Naing, John Powderly, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|May 18, 2016
Thymic stromal lymphopoietin in tonsillar follicular dendritic cells correlates with elevated serum immunoglobulin A titer by promoting tonsillar immunoglobulin A class switching in immunoglobulin A nephropathyHongxue Meng, Huining Li, Rintaro Ohe, et al.
Journal of Immunotherapy and Precision Oncology|January 16, 2025
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 StudyAung Naing, Amit Mahipal, Milind Javle, et al.
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
Pageof 40

Showing results (251-260 of 397) with videos related to

Sort By:
Pageof 40
Cancer Chemotherapy and Pharmacology|January 18, 2014
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancersJennifer J Wheler, Filip Janku, Gerald S Falchook, et al.
Carcinogenesis|October 3, 2017
Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic modelYoshiko Shimizu, Hideki Furuya, Paulette M Tamashiro, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trialsHossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2018
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With ImmunotherapyChristine M Parseghian, Madhavi Patnana, Priya Bhosale, et al.
Oncotarget|February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trialsIshwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Journal for Immunotherapy of Cancer|November 20, 2024
Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumorsMatthew H Taylor, Aung Naing, John Powderly, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|May 18, 2016
Thymic stromal lymphopoietin in tonsillar follicular dendritic cells correlates with elevated serum immunoglobulin A titer by promoting tonsillar immunoglobulin A class switching in immunoglobulin A nephropathyHongxue Meng, Huining Li, Rintaro Ohe, et al.
Journal of Immunotherapy and Precision Oncology|January 16, 2025
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 StudyAung Naing, Amit Mahipal, Milind Javle, et al.
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
Pageof 40